Corcept Therapeutics (CORT) Stock Price
Corcept Therapeutics Price
Revenue has compounded at 51.2% per year over the past 19 years to 761.41 M USD. Earnings per share have grown at 31.2% per year over the last 9 years. Corcept Therapeutics's net margin stands at 13.1%, down from 30.7% several years earlier. Analysts set a median price target of 142.50 USD, implying 20.3% above the current price. Of 12 analysts, 10 rate the stock a buy — an overall Buy consensus. The stock trades about 268% above its 52-week low.
Corcept Therapeutics stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Corcept Therapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Corcept Therapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Corcept Therapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Corcept Therapeutics Price |
|---|---|
| 9/24/2026 | 118.45 USD |
| 9/22/2026 | 117.18 USD |
| 9/21/2026 | 115.64 USD |
| 9/18/2026 | 115.01 USD |
| 9/17/2026 | 114.86 USD |
| 9/16/2026 | 111.01 USD |
| 9/15/2026 | 110.96 USD |
| 9/14/2026 | 111.80 USD |
| 9/13/2026 | 113.19 USD |
| 9/11/2026 | 110.34 USD |
| 9/10/2026 | 114.92 USD |
| 9/9/2026 | 115.70 USD |
| 9/8/2026 | 113.22 USD |
| 9/4/2026 | 111.62 USD |
| 9/3/2026 | 112.80 USD |
| 9/2/2026 | 110.43 USD |
| 9/1/2026 | 113.38 USD |
| 8/31/2026 | 113.35 USD |
| 8/30/2026 | 111.38 USD |
| 8/28/2026 | 114.58 USD |
| 8/27/2026 | 118.04 USD |
| 8/26/2026 | 119.80 USD |
| 8/25/2026 | 123.57 USD |
| 8/24/2026 | 121.59 USD |
| 8/21/2026 | 122.25 USD |
| 8/20/2026 | 121.05 USD |
| 8/19/2026 | 120.37 USD |
| 8/18/2026 | 118.00 USD |
| 8/14/2026 | 114.47 USD |
| 8/13/2026 | 110.51 USD |
Corcept Therapeutics Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Corcept Therapeutics Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEB USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEB USD |
| EBITB USD |
| EBIT MARGIN% |
| NET INCOMEB USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e | 2030e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.05 | 0.08 | 0.16 | 0.25 | 0.31 | 0.35 | 0.37 | 0.40 | 0.48 | 0.68 | 0.76 | 1.11 | 1.59 | 2.18 | 2.49 | 3.12 |
| 92.31 | 62.00 | 96.30 | 57.86 | 21.91 | 15.36 | 3.40 | 9.86 | 20.20 | 40.04 | 12.74 | 45.99 | 42.84 | 37.43 | 14.12 | 25.39 |
| 96.00 | 97.53 | 97.48 | 98.01 | 98.04 | 98.58 | 98.63 | 98.75 | 98.55 | 98.37 | 98.29 | 98.29 | 98.29 | 98.29 | 98.29 | 98.29 |
| 0.05 | 0.08 | 0.16 | 0.25 | 0.30 | 0.35 | 0.36 | 0.40 | 0.48 | 0.66 | 0.75 | 1.09 | 1.56 | 2.14 | 2.45 | 3.07 |
| – | 0.01 | 0.05 | 0.09 | 0.11 | 0.13 | 0.12 | 0.11 | 0.11 | 0.14 | 0.04 | 0.29 | 0.50 | 1.00 | 1.14 | 1.63 |
| -6.00 | 12.35 | 32.70 | 35.46 | 36.27 | 36.26 | 33.97 | 27.93 | 22.20 | 20.15 | 5.78 | 25.74 | 31.32 | 45.76 | 45.80 | 52.23 |
| -0.01 | 0.01 | 0.13 | 0.08 | 0.09 | 0.11 | 0.11 | 0.10 | 0.11 | 0.14 | 0.10 | 0.25 | 0.51 | 0.85 | 1.02 | 1.46 |
| -80.65 | -233.33 | 1,512.50 | -41.86 | 25.33 | 12.77 | 5.66 | -9.82 | 4.95 | 31.13 | -28.78 | 149.49 | 108.10 | 65.95 | 20.05 | 42.97 |
| 109.66 | 112.87 | 127.36 | 125.15 | 122.69 | 127.42 | 122.43 | 116.33 | 110.89 | 118.46 | 119.86 | 119.86 | 119.86 | 119.86 | 119.86 | 119.86 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Corcept Therapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Corcept Therapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Corcept Therapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Corcept Therapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Corcept Therapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Corcept Therapeutics stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Corcept Therapeutics Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Corcept Therapeutics business model & stock analysis
Corcept Therapeutics SWOT Analysis
Strengths
Corcept Therapeutics Inc has several strengths that contribute to its success in the pharmaceutical industry:
- Strong Product Portfolio: Corcept Therapeutics has a diverse range of patented medications, including Korlym and Cushing's syndrome treatments. This broad product portfolio reduces its dependence on a single product.
- Market Leadership: The company is one of the leading providers of medications for Cushing's syndrome and has established a strong presence in this niche market. This market leadership provides a competitive edge.
- Research and Development Capabilities: Corcept Therapeutics invests significantly in R&D, allowing it to develop innovative drugs and explore new therapeutic areas. This focus on research enables the company to stay ahead of its competitors.
- Effective Marketing and Distribution Channels: The company has established robust marketing and distribution channels, ensuring its products reach healthcare providers and patients efficiently.
- Strong Financial Performance: Corcept Therapeutics has experienced consistent revenue growth over the years, reflecting its strong financial performance. This stability provides the company with resources for future growth and investment.
Weaknesses
Despite its strengths, Corcept Therapeutics Inc also faces certain weaknesses that pose challenges to its growth and competitiveness:
- Dependency on Few Products: Despite having a strong product portfolio, the company heavily relies on a few key medications, such as Korlym. This dependency exposes Corcept Therapeutics to the risk of sales fluctuations if demand for these drugs declines.
- Regulatory Risks: As a pharmaceutical company, Corcept Therapeutics operates in a highly regulated industry. Changes in government regulations or increased scrutiny can impact the company's operations and hinder its ability to bring new medications to market.
- Limited Global Presence: The company's operations are primarily focused in the United States, which limits its market reach. Expanding into international markets could provide growth opportunities, but it also involves additional complexities and risks.
Opportunities
Corcept Therapeutics Inc can explore various opportunities to further enhance its business and drive future growth:
- Expansion into New Therapeutic Areas: By leveraging its research capabilities, the company can explore and enter new therapeutic areas to diversify its product offerings and revenue streams.
- Increasing Awareness: There is an opportunity for Corcept Therapeutics to raise awareness among healthcare providers and patients about its innovative medications, potentially capturing a larger market share.
- Strategic Partnerships: Collaborating with other pharmaceutical companies or research institutions can enable Corcept Therapeutics to access new technologies, enhance its R&D efforts, or expand its distribution network.
- Global Market Expansion: Seeking regulatory approvals and entering international markets can broaden the company's customer base and revenue potential.
Threats
Corcept Therapeutics Inc faces certain threats that may impact its business operations and market position:
- Competition: The pharmaceutical industry is highly competitive, with other companies developing similar medications for various diseases. Increased competition can result in pricing pressures and reduced market share.
- Potential Patent Challenges: As patents expire, competitors may enter the market with generic alternatives, eroding Corcept Therapeutics' market share and profitability.
- Healthcare Reforms: Changes in healthcare policies, reimbursement rates, or insurance coverage can influence the demand and affordability of medications, affecting the company's financial performance.
Corcept Therapeutics Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Corcept Therapeutics Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Corcept Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio
Corcept Therapeutics annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Corcept Therapeutics's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Corcept Therapeutics's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Corcept Therapeutics's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Corcept Therapeutics shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Corcept Therapeutics forecasts and price targets in September 2026
Analyst Price Targets 2026Corcept Therapeutics Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 7/30/2026 | Maintained | Overweight | 54 | |
| 7/30/2026 | Maintained | Buy | – | |
| 7/30/2026 | Maintained | Buy | 63 | |
| 7/29/2026 | Maintained | Buy | 63 | |
| 7/27/2026 | Downgrade | Peer PerformUnderperform | – | |
| 5/28/2026 | Maintained | Buy | – | |
| 5/28/2026 | Maintained | Buy | 63 | |
| 5/13/2026 | Upgrade | NeutralBuy | 49 | |
| 5/4/2026 | Maintained | Buy | – | |
| 5/1/2026 | Maintained | Overweight | 54 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Corcept Therapeutics Earnings Calls
Corcept Therapeutics Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/4/2026 | 0.81USD | - | 323.90 MUSD | - | 2026 Q3 |
| 7/29/2026 | 0.02USD | 0.36USD | 221.15 MUSD | - | 2026 Q2 |
| 4/30/2026 | -0.11USD | -0.30USD | 185.27 MUSD | - | 2026 Q1 |
| 2/24/2026 | 0.33USD | 0.20USD | 254.94 MUSD | - | 2025 Q4 |
| 11/4/2025 | 0.18USD | 0.16USD | 255.35 MUSD | - | 2025 Q3 |
| 7/31/2025 | 0.23USD | 0.29USD | 244.58 MUSD | - | 2025 Q2 |
| 5/5/2025 | 0.17USD | 0.17USD | 216.68 MUSD | - | 2025 Q1 |
| 2/26/2025 | 0.37USD | 0.26USD | 200.12 MUSD | - | 2024 Q4 |
| 10/30/2024 | 0.28USD | 0.41USD | 198.02 MUSD | - | 2024 Q3 |
| 7/29/2024 | 0.23USD | 0.32USD | 162.08 MUSD | - | 2024 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Corcept Therapeutics stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Corcept Therapeutics shareholder structure
| % | Name |
|---|---|
10.12716% | |
9.20563% | |
7.89417% | |
6.34128% | |
5.99653% | |
4.79929% |
Corcept Therapeutics Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
15.20% | SEC ↗ | |
12.50% | SEC ↗ | |
11.20% | SEC ↗ | |
11.06% | SEC ↗ | |
10.90% | SEC ↗ | |
10.23% | SEC ↗ | |
9.40% | SEC ↗ | |
7.50% | SEC ↗ | |
7.25% | SEC ↗ | |
6.95% | SEC ↗ |
Corcept Therapeutics Executives and Management Board
15 members · avg. age 61 · 20 % women
Dr. Joseph Belanoff (67)
President, Chief Executive Officer, Co-Founder, Director · since 1999
9.89 M USD
Management
Mr. Gary Robb (62)
Chief Business Officer, Secretary
Mr. William Guyer (57)
Chief Development Officer
Mr. Sean Maduck (48)
President - Corcept Endocrinology · since 2022
Mr. Atabak Mokari (48)
Chief Financial Officer, Treasurer
Dr. Hazel Hunt (65)
Chief Scientific Officer
Mr. Joseph Lyon (47)
Chief Accounting and Technology Officer
Board of Directors
Mr. James Wilson (81)
Independent Chairman of the Board · since 1999
Mr. Gregg Alton (59)
Independent Director
Mr. David Mahoney (70)
Independent Director
Dr. Gillian Cannon (61)
Independent Director
Mr. George Baker (82)
Independent Director
Mr. Joshua Murray (41)
Independent Director
Frequently asked questions about Corcept Therapeutics
The business model of Corcept Therapeutics Inc. revolves around developing, manufacturing, and commercializing drugs for the treatment of severe metabolic, psychiatric, and oncologic disorders. As a pharmaceutical company, Corcept focuses on discovering innovative therapies to address unmet medical needs. With a particular emphasis on the research and development of selective cortisol modulators, the company aims to provide effective solutions for patients suffering from disorders caused by the excess production of cortisol. Corcept Therapeutics Inc. aims to improve patient outcomes by harnessing its expertise in the field of selective cortisol modulation and delivering innovative medical therapies.
Corcept Therapeutics Inc is primarily active in the pharmaceutical and healthcare industries.
The main competitors of Corcept Therapeutics Inc in the market are pharmaceutical companies such as Novartis, Pfizer, and Eli Lilly and Company.
Corcept Therapeutics Inc is a pharmaceutical company specializing in the development and commercialization of drugs for the treatment of severe metabolic, psychiatric, and oncologic disorders. Founded in 1998, Corcept has its headquarters in Menlo Park, California. The company's flagship product, Korlym, is an FDA-approved medication for patients with Cushing's syndrome. Corcept's focus on cortisol-related disorders has led to the exploration of additional treatment indications. With a dedicated research and development team, Corcept Therapeutics Inc continues to innovate in the field of endocrinology and neurobiology, striving to improve patients' lives worldwide.
Corcept Therapeutics Inc has achieved significant milestones in its history. One notable achievement is the approval and commercialization of its flagship drug, Korlym, by the U.S. Food and Drug Administration (FDA). This medication is used to treat patients with Cushing's syndrome, a rare and severe endocrine disorder. Additionally, Corcept has successfully expanded the approved indications for Korlym to include the treatment of patients with hyperglycemia secondary to Cushing's syndrome. The company has also completed several clinical trials, demonstrating the efficacy and safety of its products. Overall, Corcept Therapeutics Inc has made remarkable strides in advancing the field of endocrinology with its innovative treatments.
Corcept Therapeutics Inc is primarily present in the United States.
Corcept Therapeutics Inc represents values of innovation, dedication, and patient-centric approach. As a biopharmaceutical company, Corcept is committed to developing innovative medications to improve patient lives. Their corporate philosophy revolves around the belief that patients are at the heart of what they do, and they strive to address unmet medical needs. Corcept Therapeutics Inc employs cutting-edge scientific research and partnerships to create effective therapies for serious disorders, including Cushing's syndrome. With a focus on scientific excellence, patient well-being, and dedication to improving healthcare outcomes, Corcept Therapeutics Inc stands out in the biopharmaceutical industry. Keep up with the latest developments and news regarding Corcept Therapeutics Inc on our website.
Analysts currently set an average price target of 125.33 USD for the Corcept Therapeutics stock (median: 142.50 USD), implying +11.0 % versus the latest price. The consensus is based on 12 analyst ratings.
12 analysts currently rate the Corcept Therapeutics stock: 10 recommend buying, 1 holding and 1 selling. For 2026, analysts expect Corcept Therapeutics to generate revenue of 1.11 B USD and earnings per share of 2.06 USD.
Converted at the current exchange rate, the Corcept Therapeutics share trades at 103.92 EUR (118.45 USD).
The Corcept Therapeutics share (CORT) is listed on 7 stock exchanges, including: NASDAQ (CORT), London (0I3Q.L), SIX (Zürich) (HTD.SW), Frankfurt (HTD.F), München (HTD.MU), Düsseldorf (HTD.DU).
Corcept Therapeutics Inc is a pharmaceutical company focused on the development of medications to treat serious diseases such as Cushing's syndrome and solid tumors. The company operates in three business segments: (1) medication development and commercialization, (2) clinical studies, and (3) licensing fees from third-party companies. Corcept develops medications that block cortisol receptors, such as Korlym for treating Cushing's syndrome. They also conduct clinical studies to further develop and prove the efficacy of their medications. Additionally, the company generates revenue through licensing agreements with third-party companies. Corcept has established partnerships with IBSA Pharma and Teva Pharmaceutical Industries to market Korlym in Europe and Israel. Overall, Corcept focuses on addressing medical challenges, aligning its business segments, and advancing the clinical development of its products. It has become a leading company in this field through its specialization in a specific disease and the development of drugs to treat it. Collaborations and a strong focus on clinical research have contributed to Corcept's sustainable business model aimed at long-term growth and success in improving healthcare. The company's wide range of products is tailored to its core competencies and supports its comprehensive healthcare model.
The expected revenue of Corcept Therapeutics is 1.11 B USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Corcept Therapeutics is 247.27 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Corcept Therapeutics is currently 57.42. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Corcept Therapeutics stock.
The price-to-sales ratio (P/S) of Corcept Therapeutics is currently 12.77. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Corcept Therapeutics stock.
The Eulerpool Quality Score for Corcept Therapeutics is 6/10.
The ISIN of Corcept Therapeutics is US2183521028. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Corcept Therapeutics is 529882. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Corcept Therapeutics is CORT. The ticker symbol is used to trade Corcept Therapeutics shares on the stock exchange.
Corcept Therapeutics paid dividends every year for the past 0 years.
Corcept Therapeutics is assigned to the 'Health' sector.
The dividends of Corcept Therapeutics are distributed in USD.
Corcept Therapeutics stock
Corcept Therapeutics Peer Group
Corcept Therapeutics Ticker
Corcept Therapeutics FIGI
All fundamentals and in-depth analysis of Corcept Therapeutics
Our stock analysis for Corcept Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Corcept Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.